News >

Expert Predicts the Trajectory of Biosimilars in Oncology

Angelica Welch
Published: Friday, Jun 08, 2018

Haythem Y. Ali, MD

Haythem Y. Ali, MD
Several biosimilars for trastuzumab (Herceptin) are under investigation, with one achieving an FDA approval at the close of 2017. The FDA approved MYL-1401O (Ogivri; trastuzumab-dkst) for use in HER2-positive breast cancer, as well as HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.

Data from the phase III HERITAGE trial presented at the 2018 ASCO Annual Meeting showed that adding MYL-1401O (Ogivri; trastuzumab-dkst) to a taxane as initial therapy followed by MYL-1401O monotherapy as maintenance produced a nearly identical progression-free survival (PFS) rate at 48 weeks compared with trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.1

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication